Cambridge, Mass., October 19, 2023 – In a pioneering move, Flagship Pioneering announces the fusion of Laronde and Senda Biosciences, birthing Sail Biomedicines—a trailblazing force in the evolution of fully programmable medicines poised to redefine patient care. Dr. Guillaume Pfefer, Ph.D., and MBA, the current CEO-Partner at Flagship Pioneering, will spearhead Sail as its CEO and board member, with Dr. John Mendlein, Executive Partner at Flagship Pioneering, assuming the role of Executive Chairman.
Sail Biomedicines leverages over eight years of collaborative data and platform development from Laronde and Senda Biosciences. Senda’s platform, utilizing a universal chemical code within natural nanoparticles, allows precise deployment of payloads, like translatable RNA, to designated cells.
Simultaneously, Laronde’s groundbreaking Endless RNA (eRNA), a synthetic RNA class, presents substantial therapeutic potential.
Dr. Mendlein underscores the potential of Endless RNA to inaugurate a new era of programmable medicines, deliverable to cells and tissues through unique deployment molecules. He envisions leveraging proprietary generative AI technologies and rapid prototyping as pivotal for achieving breakthroughs beyond current human comprehension.
Dr. Pfefer highlights Sail’s deployment platform, utilizing natural nanoparticles to transport biomolecules into human cells with unique tropism, potency, and redosability. His vision is to expedite the development of new product candidates, form strategic partnerships, and unlock diverse value pools for the swift delivery of transformative vaccines and therapies.
Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering, expresses confidence in Sail Biomedicines, stating, “I am confident the combined leadership team and board will carry forward this company to realize its bold ambitions and ultimately deliver maximum impact for patients.”
The Sail Biomedicines Board of Directors, including Drs. Mendlein and Pfeffer, comprises individuals from the Laronde and Senda Biosciences boards, alongside experts from Incyte, ADC Therapeutics, Massachusetts Institute of Technology, and Flagship Pioneering.
About Sail Biomedicines
Sail Biomedicines pioneers the integrative design and deployment of fully programmable medicines, combining programmable circular RNA technology (Endless RNA™ or eRNA) with an industry-leading platform of programmable nanoparticles.
About Flagship Pioneering
Flagship Pioneering is a biotechnology company inventing and building platform companies, each harboring the potential for transformative products in human health or sustainability. Since 2000, Flagship has shepherded over 100 ventures, resulting in over $90 billion in aggregate value, with a current ecosystem comprising 43 companies.
Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Skyline Therapeutics Receives FDA Orphan Drug Designation for Gene Therapy for Retinitis Pigmentosa
BOSTON & SHANGHAI, September 2, 2024 – Skyline Therapeutics, a gene therapy company focused on innovative treatments for rare and severe diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SKG1108....
Novavax Receives Emergency Use Authorization for Updated Covid-19 Vaccine
Novavax has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its updated Covid-19 vaccine, NVX-CoV2705, joining other vaccine manufacturers in addressing evolving virus variants. The EUA permits the use of Novavax's...
Turn Biotechnologies Reports Historic Skin Cell Rejuvenation Breakthroughs at ESDR this Week
Company will present data from its successful rejuvenation of fibroblasts and keratinocytes to influential gathering of international dermatologists MOUNTAIN VIEW, Calif., Sept. 4, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicines and...
H5 influenza vaccines: What needs to be done to reduce the risk of a pandemic
As the global threat of H5N1 influenza looms with outbreaks across species and continents including the U.S., three international vaccine and public health experts say it is time to fully resource and support a robust strategy to address this and future potential...
Related Services
Plasmids GMP Services
AAV GMP Services
